Business Wire

George Eyles Appointed Chief Executive Officer of Netherlands-based Maccs

Del

Maccs, the leading provider of theatrical distribution software for the global film industry and a company of Vista Group International (NZX & ASX: VGL), is delighted to announce the appointment of George Eyles to the role of Chief Executive Officer. As CEO, Mr. Eyles will be responsible for Maccs’ global operations, spanning customers in more than 50 countries.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180606005451/en/

George Eyles, new Maccs CEO (Photo: Business Wire)

George Eyles, new Maccs CEO (Photo: Business Wire)

Mr. Eyles will join Maccs from his current role of Managing Director of Digital Cinema, EMEA for Deluxe Technicolor. He has worked at Deluxe since Deluxe and Technicolor created a joint venture for cinema in 2015. Mr Eyles is very familiar with Maccs from his time at Deluxe and positioned to transfer his proven leadership skills to continue to build Maccs’ strong future.

Mr. Eyles has over 16 years industry experience in distribution of digital content, including advertising and cinema. Prior to the Deluxe Technicolor joint venture, he was responsible for Technicolor’s worldwide digital cinema strategy leading the business development team located in London and Los Angeles.

He joined Technicolor from Arqiva where he was responsible for the deployment of a Pan-European electronic delivery network for cinema, working closely with studios and exhibitors. George was also responsible for creating Arqiva’s ‘Live Event’ services delivering hundreds of live alternative events to cinemas around the world.

Mr. Eyles says, “Maccs is highly regarded throughout the industry and well known for supporting and bringing innovation to its clients. The organization and its professionals around the world are first class, and I’m looking forward to being part of the Vista Group team and the innovation and vision they continue to bring to the industry.”

Group CEO Kimbal Riley commented, “I’m delighted to have an executive of the caliber of George Eyles join the Group as leader of Group company Maccs. George is a high energy, highly capable operator, with a strong track record, and we are looking forward to his impact working with Maccs to continue to grow a business that has been ‘redefining movie distribution’ for our customers since 1995.”

George will take up his new position in August 2018.

About Maccs:
Maccs develops market leading theatrical distribution software for the global film industry. Maccs software is used by more than 100 distributors to distribute films in more than 50 countries. Clients range from small independent distributors to major international distributors. The Maccs software portfolio includes an integrated theatrical distribution system, with Rights & Royalties & Print & Advertising modules. It also includes MaccsBox & DCinemaHub, an online platform that automates content ordering, delivery reporting, gross box office & eBOR collection & invoicing. Maccs’s customers include some of the world’s largest movie studios, such as Paramount Pictures International & Warner Bros. In 2015, Warner Bros. USA licensed Maccs to operate its theatrical distribution in the USA, adding to its international use of Maccs, the first time a studio has centralised its theatrical distribution operations under one technology platform. A company of Vista Group International (NZX: VGL, ASX: VGL), Maccs’s operations are based in Los Angeles, The Netherlands, Germany, & Australia.
Website: www.maccs.com
LinkedIn: www.linkedin.com/company/maccs-international-bv

About Vista Group International:
Vista Group International (Vista Group) is a public company, listed on both the New Zealand and Australian stock exchanges (NZX & ASX: VGL). The Group provides software and additional technology solutions across the global film industry. Cinema management software is provided by Vista Entertainment Solutions (Vista Cinema), the core business of the Group. Movio (authority in moviegoer data analytics), Veezi (cloud-based SaaS software for the Independent Cinema Market), movieXchange (connecting the movie industry to simplify the promotion and sale of movie tickets), Maccs (film distribution software), Numero (box office reporting software for film distributors and cinemas), Cinema Intelligence (business intelligence solutions), Powster (creative studio and marketing platform for movie studios) and Flicks (moviegoer ‘go to’ portal for movie information) provide an innovative range of complementary products across additional film industry sectors, from production and distribution, to cinema exhibition through to the moviegoer experience. Vista Group has offices located in New Zealand (Auckland HQ), Sydney, Los Angeles, London, Shanghai, Beijing, Mexico City, South Africa, the Netherlands and Romania.
Website: www.vistagroup.co
LinkedIn: www.linkedin.com/company/vista-group-limited

Contact information

Vista Group International/Auckland, NZ
Christine Fenby, +64 21 727 006
christine.fenby@vista.co
or
For Vista Group International/USA
Maggie Begley/MBC
+1 310 390 0101
maggie@mbcprinc.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 05:00Pressemelding

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 04:05Pressemelding

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth15.8.2018 23:40Pressemelding

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 22:37Pressemelding

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 17:43Pressemelding

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.

Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovation15.8.2018 17:05Pressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has been honored with a Stevie® Award in the Innovation in Customer Service Management, Planning & Practice category for its ultra-responsive, premium level service in the Asia-Pacific region. This honor marks the Company’s 12th Stevie Award win this year, and the second consecutive year the Company has been recognized by the Asia-Pacific Stevie Awards. Rimini Street recently earned Stevie Awards in several categories, including Company of the Year from the 2018 American Business Awards® and Customer Service Department of the Year from the 2018 Stevie Awards for Sales & Customer Service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005580/en/ Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovat